Fueled with a fresh cash injection, Cullinan expands its pipeline with a bid to develop a new combination drug for the checkpoint class
Fresh off of a $98.5 million raise, Patrick Baeuerle’s team at Cullinan Oncology has a new subsidiary they’re bringing into the pack.
This one, their 8th drug development operation, is called Cullinan MICA, named after a target they believe has broad applicability against multiple cancers, quite likely in a potential combination with the checkpoints that have been changing up the practice of medicine for cancer patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.